Coronary heart disease prevention as the primary goal in contemporary trials in the treatment of hypertension

被引：1
作者：
Sever P.S. [1 ]
机构：
[1] Clinical Pharmacology, Imperial College, School of Medicine
来源：
Current Hypertension Reports | 2000年 / 2卷 / 4期
关键词：
Angiotensin Converting Enzyme; Calcium Channel Blocker; Angiotensin Converting Enzyme Inhibitor; Doxazosin; Nisoldipine;
D O I：
10.1007/s11906-000-0047-6
中图分类号：
学科分类号：
摘要：
The prevention of coronary heart disease remains one of the greatest challenges for antihypertensive therapy. Previous trials have identified a shortfall in the protection of hypertensive patients against coronary heart disease compared with that predicted from observational studies. The present question is whether newer classes of drugs or drug combinations (calcium channel blockers, angiotensin converting enzyme inhibitors) can redress the shortfall compared with older agents (diuretics, (3-blockers). However, to answer this question only two trials (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial [ALLHAT] and Anglo Scandinavian Cardiac Outcomes Trial [ASCOT]) are of sufficient size to be adqeuately powered to address this issue. ALLHAT and ASCOT have completed randomization of patients and will report on morbidity and mortality within 3 to 4 years. Copyright © 2000 by Current Science Inc.
引用
收藏
页码：418 / 420
页数：2
相关论文
共 19 条
  • [1] Collins R., Peto R., Antihypertensive drug therapy: Effects on stroke and coronary heart disease, Textbook of Hypertension, pp. 1156-1164, (1994)
  • [2] MacMahon S., Peto R., Cutler J., Et al., Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias, Lancet, 335, pp. 765-774, (1990)
  • [3] Miall W.E., Greenberg G., Mild Hypertension: Is There Pressure to Treat? An Account of the MRC Trial, (1987)
  • [4] Grimm R.H., Leon A.S., Hunninghake D.B., Et al., Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients, Ann Intern Med, 94, pp. 7-11, (1981)
  • [5] Dahlof B., J Hypertens, 16, SUPPL. 3, (1998)
  • [6] Davis B.R., Cutler J.A., Gordon D.J., Et al., Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT), Am J Hypertens, 9, pp. 342-360, (1996)
  • [7] Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihyper tensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordina tors for the ALLHAT Collaborative Research Group, JAMA, 283, pp. 1967-1975, (2000)
  • [8] Furberg C.D., Psaty B.M., Mayer J.V., Nifedipine. Dose related increase in mortality in patients with coronary heart disease, Circulation, 92, pp. 1326-1331, (1995)
  • [9] Psaty B.M., Heckbert S.R., Koepsell T.D., Et al., The risk of MI associated with antihypertensive drug therapies, JAMA, 274, pp. 620-625, (1995)
  • [10] Pahor M., Guralnik J.M., Corti M.C., Et al., Long term survival and use of antihypertensive medications in older persons, J Am Geriatr Soc, 43, pp. 1-7, (1995)
12